Ampsource Biopharma Shanghai Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 5, 2027The maintenance fee for Linker Peptide for Constructing Fusion Protein (US 11,833,212) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Antibody Against TIM-3 and Application Thereof (US 11,884,725) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Dual-function protein for lipid and blood glucose regulation (US 11,981,718) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,123,438 | Linker Peptide for Constructing Fusion Protein In force · High confidence | In force | High confidence | |
| US 11,833,212 | Linker Peptide for Constructing Fusion Protein In force · High confidence | In force | High confidence | |
| US 11,472,863 | Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,471,513 | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same In force · USPTO record | In force | USPTO record | |
| US 11,981,718 | Dual-function protein for lipid and blood glucose regulation In force · USPTO record | In force | USPTO record | |
| US 11,884,725 | Antibody Against TIM-3 and Application Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 abandoned · 5 no status recorded